JBT is a clinical stage biopharmaceutical company developing a non-psychotropic synthetic derivative of THC, the active ingredient in marijuana. The first indication being pursued is scleroderma, a multibillion dollar orphan indication with high mortality and effective therapies. The first new class of analgesic agents in decades, the firm's lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. JB Therapeutics has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.
